Readoutin 14d
Incyte Corporation — Povorcitinib
Phase 3 primary completion: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Hidradenitis Suppurativa (HS)